News + Resources
Keep up with the latest
Featured
Recent
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
This Scientist Is Building Custom Gene-Editing Tools
November 11, 2024
This Scientist Is Building Custom Gene-Editing Tools
November 11, 2024
Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024
October 30, 2024
Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024
October 30, 2024
All Stories
News
CRISPR drug licensing deals secure $21bn in top three therapy areas over five years
March 28, 2024
Pharmaceutical Technology
Read Now
Press
CRISPR drug licensing deals secure $21bn in top three therapy areas over five years
March 28, 2024
Pharmaceutical Technology
Read Now
News
Scribe Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
March 6, 2024
Read Now
Press
Scribe Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
March 6, 2024
Read Now
News
Benjamin Oakes and the Promise of CRISPR
March 5, 2024
Eureka
Read Now
Press
Benjamin Oakes and the Promise of CRISPR
March 5, 2024
Eureka
Read Now
News
CRISPR Partnerships Propel Precision Medicine
February 20, 2024
CRISPR Medicine News
Read Now
Press
CRISPR Partnerships Propel Precision Medicine
February 20, 2024
CRISPR Medicine News
Read Now